Stock comparison
IDEXX Laboratories
Mettler-Toledo International
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$42.11B
Sector
Healthcare
MTD
Mettler-Toledo International
Market cap
$20.85B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | MTD | Winner |
|---|---|---|---|
| Warren Buffett | 67B | 60C | IDXX |
| Benjamin Graham | 72B | 33F | IDXX |
| Philip Fisher | 67B | 54C | IDXX |
| Peter Lynch | 63C | 52C | IDXX |
| Joel Greenblatt | 75B | 58C | IDXX |
| Charlie Munger | 79B | 63C | IDXX |
| Terry Smith | 76B | 62C | IDXX |
Side-by-side metrics
| Metric | IDXX | MTD |
|---|---|---|
| Market cap | $42.11B | $20.85B |
| P/E (TTM) | 39.0x | 23.9x |
| EV/EBIT | 31.6x | 20.6x |
| ROIC (TTM) | 40.66% | 36.09% |
| Gross margin | 62.05% | 57.79% |
| Net margin | 24.63% | 21.4% |
| Revenue CAGR 5y | 7.56% | 2.01% |
| EPS CAGR 5y | 10.79% | 6.12% |
| Debt / Equity | 0.7x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Revenue CAGR 5y7.56%vs 2.01%+73%
- Market cap$42.11Bvs $20.85B+50%
- EPS CAGR 5y10.79%vs 6.12%+43%
- Net margin24.63%vs 21.4%+13%
MTD leads on
- Debt / Equity-vs 0.7x+101%
- P/E (TTM)23.9xvs 39.0x+39%
- EV/EBIT20.6xvs 31.6x+35%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.